zinc finger protein 419Genealiases: ZAPHIR · ZNF419A
Q-omics provides the consensus-scored ZNF419 profile across patient tissues and cancer cell-line models. ZNF419 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF419 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ZNF419 protein abundance shows 24,550 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, HNSC, and LUAD as cancer lineages where ZNF419 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF419 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF419 survival associations across molecular data types. ZNF419 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF419 RNA expression–survival associations across cancer types. High ZNF419 expression shows unfavorable associations in MESO, LGG, ACC, LIHC and PRAD, but favorable associations in PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF419 RNA expression.
This table summarizes ZNF419 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF419. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF419 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, CHOL and KIRC. The HNSC box plot shows higher ZNF419 RNA expression in tumor versus normal tissue (log2 FC = +0.353, t-test p < 0.001).
This table shows molecular features associated with ZNF419 in patient tissues and cancer cell lines. In patient samples, ZNF419 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF419 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
